For those who are fretting over efficacy not being good enough. The latest PR doesn't say the submittal for EUA for U.S./UK is conditional on potential results from the trial. It says it will be submitted, which tells you all about confidence they have in the data.

Quote:

---

COVID-19 Phase 2 topline report to be submitted for consideration of emergency approval of leronlimab for patients with mild-to-moderate symptoms to U.K. and other countries following submission to the U.S. FDA next week

---